<DOC>
	<DOCNO>NCT01289080</DOCNO>
	<brief_summary>This trial open-label , multi-center , parallel-arm , single-dose trial 2 group : 1 group subject normal renal function 1 group severely renally impaired subject .</brief_summary>
	<brief_title>Trial Evaluating OPC-34712 Subjects With Normal Renal Function Renally Impaired Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<criteria>Male female ( nonchildbearing potential ) subject ≥ 18 year age . Ability provide write informed consent prior initiation trialrelated procedure , ability , opinion principal investigator , comply requirement trial . Male female subject surgically sterile ; female subject postmenopausal least 12 consecutive month ( confirm follicle stimulate hormone sample Screening ) ; male subject agree remain abstinent practice doublebarrier form birth control refrain sperm donation trial Screening 90 day last dose investigational medicinal product . Body weight within ± 35 % ideal body weight defined 1983 Metropolitan Height Weight Tables ( see Appendix 4 , Appendix 5 , Appendix 6 ) . Minimum body weight less 50 kg . Inclusion Criteria Subjects Normal Renal Function Subjects good health determine medical history , physical examination , serum chemistry , hematology , urinalysis , hepatitis B C test , human immunodeficiency virus ( HIV ) test . Creatinine clearance &gt; 80 mL/min indicate normal renal function . Inclusion Criteria Renally Impaired Subjects Renally impaired subject may take medication , opinion clinical investigator sponsor , believe therapeutic subject ( affect OPC34712 absorption , distribution , metabolism , elimination ) . Inhibitors inducer CYP3A4 inhibitor CYP2D6 allow . Creatinine clearance &lt; 30 mL/min indicate severe renal impairment . Subjects renal impairment relatively stable renal function determine creatinine clearance otherwise generally good health . Clinically significant abnormality past medical history , screen physical examination , investigator 's sponsor 's opinion may place subject risk interfere outcome variable include absorption , distribution , metabolism , excretion drug . Any surgical medical condition ( active chronic ) may interfere drug absorption , distribution , metabolism , excretion , condition may place subject risk . History drug and/or alcohol abuse within 2 year prior Screening . A positive urine alcohol test and/or urine drug screen substance abuse Screening upon checkin trial site . The donation blood plasma within 30 day prior dose . Any history significant bleeding hemorrhagic tendency . History current hepatitis carrier hepatitis B surface antigen ( HBsAg ) and/or hepatitis C antibody ( antiHCV ) . History acquire immunodeficiency syndrome determine human immunodeficiency virus ( HIV ) positive Screening . Use investigational drug product , participation drug trial within 30 day prior dose . Previous exposure OPC34712 . History clinically significant drug allergy sensitivity . Subjects pregnant breastfeeding . A negative serum pregnancy test must confirm prior administration trial medication female subject . Subjects supine pulse rate , rest ≥ 3 minute , outside range 40 90 bpm . The sponsor may allow exception deem clinically significant . Exclusion Criteria Healthy Subjects Clinically significant abnormal finding serum chemistry , hematology , urinalysis result obtain Screening Day 1 . Use prescription , overthecounter , herbal medication vitamin supplement within 14 day prior dose antibiotic within 30 day prior dose . The sponsor may allow exception medication 's administration deem unlikely impact pharmacokinetic result . Inhibitors inducer CYP3A4 inhibitor CYP2D6 allow . Subjects supine , sit , stand blood pressure , rest ≥ 3 minute , high 130/80 mmHg low 100/50 mmHg . The sponsor may allow exception deem clinically significant . Exclusion Criteria Renally Impaired Subjects Subjects undergone renal transplant . Renally impaired subject may take medication , opinion clinical investigator sponsor , believe therapeutic subject ( affect OPC34712 absorption , distribution , metabolism , elimination ) . Inhibitors inducer CYP3A4 inhibitor CYP2D6 allow . Clinically significant abnormal finding serum chemistry , hematology , urinalysis result obtain Screening Day 1 , associate underlying renal condition stable medical condition consistent disease process . Subject require dialysis expect require dialysis within 45 day . Subjects supine , sit , stand blood pressure , rest ≥ 3 minute , high 160/95 mmHg low 100/50 mmHg . The sponsor may allow exception deem clinically significant . Subjects evidence delirium . Clinically relevant change electrocardiogram atrioventricular block , prolongation QRS complex 120 msec ( male female subject ) , QTcF interval ≥ 450 msec . Any subject , opinion sponsor investigator , participate trial . Consumption alcohol and/or food beverage contain methylxanthines , grapefruit , grapefruit juice , Seville oranges , Seville orange juice within 72 hour prior dose . Use drug know suspect inhibit stimulate hepatic drug metabolism enzyme within 30 day prior Screening . Exposure substance know stimulate hepatic microsomal enzyme within 30 day prior Screening end trial ( eg , occupational exposure pesticide , organic solvent ) . History serious mental disorder . Major surgery digestive tract ( exclude appendectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>psychiatric disorder</keyword>
	<keyword>renal failure</keyword>
</DOC>